Genopole: Biotherapies At The Heart Of Its History
Genopole is renowned for its scientific excellence in biotherapies. It is home to two French pioneers in the sector: Genethon for gene therapies in rare diseases, and I-Stem for the study of human pluripotent stem cells and their use in cell therapies. Indeed, Zolgensma, the first gene therapy to be approved for the childhood neuromuscular disease spinal muscular atrophy, was the fruit of research done at Genethon.
Genopole is a center of excellence in biotechnologies. It is the leader in Europe and a leader in the world for the development and production of advanced therapy medicinal products.
Genopole: A Fertile Ecosystem
The model developed by Genopole, that is, a biocluster uniting research, entrepreneurship, training and medicine, has shown its potential. An industrial biotherapies sector has come to be at Évry-Courcouronnes in partnership with national, European and global networks. Today, the value chain is complete, from R&D through to GMP production: initial and continuous training, academic research, tech- nology transfer accelerator for rare and common diseases, businesses providing R&D and services, a stem cell bank under construction and a gene therapy production facility.
